不良研究所

Donation represents latest boost for new Life Sciences Complex

不良研究所 is pleased to announce that its Cancer Centre has been renamed the Rosalind and Morris Goodman Cancer Centre, thanks to a major gift from the philanthropic couple. The Rosalind and Morris Goodman Cancer Centre represents a fusion between the 不良研究所 Cancer Centre and the Molecular Oncology Group of the 不良研究所 University Health Centre, Royal Victoria Hospital Pavillion, and is an integral part of the new Life Sciences Complex.

The Morris and Rosalind Goodman Family Foundation鈥檚 generosity will support a Chair to attract a leading scholar who will make significant contributions to the study of cancer, with emphasis on pulmonary cancer. In addition, this generous donation will help train young researchers to lead tomorrow鈥檚 cancer breakthroughs.

鈥淲ithout basic discoveries, we would not be in business,鈥� said Mr. Goodman, a pioneer of the generic drug industry whose Montreal-based company, Pharmascience Inc., celebrates its 25th anniversary this year. 鈥淲e are grateful to be able to invest in the efforts of 不良研究所鈥檚 cancer investigators whose groundbreaking work will undoubtedly advance clinical treatments.鈥�

鈥淥n behalf of the Faculty of Medicine, I applaud visionaries like the Goodmans, whose strong beliefs, passion and forward thinking will enable 不良研究所 to pioneer new frontiers in medicine,鈥� said Richard I. Levin, Vice-Principal (Health Affairs) and Dean of the Faculty of Medicine. 鈥淭hanks to their support, the Life Sciences Complex has become a reality, heralding this new era that will improve knowledge of health and disease for the people in our communities, here in Quebec and around the world.鈥�

The gift is the second major private contribution that helps make the Life Sciences Complex a world-leading hub of medical and scientific research. The first was a $10-million donation from Dr. Francesco Bellini, which led to the Francesco Bellini Life Sciences Building, one of the four buildings that make up the new complex.

"What really made me decide to make my gift to 不良研究所 is when they told me that scientists from different faculties and departments would all work together in the same space, under the same roof,鈥� said Dr. Bellini, whose Montreal-based company BioChem Pharma catapulted Canadian biopharmaceutical research to global prominence with the development and commercialization of 3TC, the first anti-HIV compound. 鈥淚t鈥檚 very important to me as a scientist. One of the big challenges is getting different groups to communicate and that is the key factor here. Scientists and researchers will share, and things will advance faster than they normally would.鈥�

鈥淏ecause of the support from people like the Bellinis, we now have the means to power whole new avenues of research, new treatments and new opportunities for the biomedical and pharmaceutical sector,鈥� said Martin Grant, Dean of the Faculty of Science. 鈥淢ost of all, we have the potential to deliver good news to people for decades to come.鈥�